Blood Coagulants Market Research Report– Middle East & Africa forecast to 2023

Blood Coagulants Market Research Report– Middle East & Africa forecast to 2023

ID: MRFR/HC/2027-CRR | July, 2017 | Region: Global | 53 pages | Cooked Research Reports

Blood Coagulants Market Information, By Types (Coagulation Factor, others), By Indication (Haemophilia, Surgery, other Bleeding Disorders – Middle East & Africa Forecast till 2023


Market Synopsis of MEA Blood Coagulants Market


Market Scenario


Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding. The Middle East & Africa blood coagulant market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A  research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients


The Middle East & Africa blood coagulant market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.


The market is expected to grow at the CAGR of 9.5% during the forecast period 2017-2023


 


Figure- MEA blood coagulants market, by Country 2016 (%)

MEA blood coagulants market


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis


 


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 


Research Methodology:


MEA blood coagulants market research


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 


Segmentation                                                                                                                                      


The MEA blood coagulants market is segmented on the basis of types, indications, and by country.


On the basis of types, the market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.


On the basis of indication, the market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.


On the basis of country, the market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa. 


Regional Analysis


The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country. 


Key Findings:



  • Hemophilia segment dominates the market with nearly 45.5% share of the MEA market

  • MEA coagulation factor market is projected to reach about USD 141.68 million by 2023

  • MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016

  • UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023


Key Players for MEA Blood Coagulants Market


Some of the major players in this market are: Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

2.1 Research Process 10

2.2 Primary Research 11

2.3 Secondary Research 11

2.4 Market Size Estimation 11

2.5 Forecast Model 12

3.1 Introduction 13

3.2 Drivers 14

3.2.1 Bleeding disorder and related conditions will push the demands on health systems (Impact weightage 75%) 14

3.2.2 Rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders are expected to boost the growth of the market (Impact weightage 25%) 15

3.3 Restrains 16

3.3.1 Lack of R&D capabilities: (Impact weightage 45%) 16

3.3.2 Counterfeit Drugs (Impact weightage 35%) 17

3.3.3 Lack of Awareness (Impact weightage 20%) 18

4.1 Introduction 19

4.2 Coagulation Factor 22

4.2.1 Recombinant Coagulation Factor 23

4.2.2 Plasma Derived Coagulation Factor 24

5.1 Introduction 25

5.2 Haemophilia 27

5.3 Surgery 28

5.4 Other Bleeding Disorders 29

6.1 Introduction 30

6.2 Saudi Arabia (KSA) 32

6.3 United Arab Emirates (UAE) 34

6.4 Qatar 36

6.5 Oman 38

6.6 Kuwait 40

6.7 Egypt 42

6.8 Rest of Middle East & Africa 44

7.1 Pfizer 46

7.1.1 Company Overview 46

7.1.2 Financials 46

7.1.3 Products 46

7.1.4 Strategies 46

7.1.5 Key Developments 46

7.2 Bayer AG 47

7.2.1 Company Overview 47

7.2.2 Financials 47

7.2.3 Products 47

7.2.4 Strategies 47

7.2.5 Key Developments 47

7.3 Novo Nordisk AS 48

7.3.1 Company Overview 48

7.3.2 Financials 48

7.3.3 Products 48

7.3.4 Strategies 48

7.3.5 Key Developments 48

7.4 Shire 49

7.4.1 Company Overview 49

7.4.2 Financials 49

7.4.3 Products 49

7.4.4 Strategies 49

7.5 SOBI 50

7.5.1 Company Overview 50

7.5.2 Financials 50

7.5.3 Products 50

7.5.4 Strategies 50

7.5.5 Key Developments 50

7.6 Octapharma 51

7.6.1 Company Overview 51

7.6.2 Financials 51

7.6.3 Products 51

7.6.4 Strategies 51

7.6.5 Key Developments 51

7.7 CSL Limited 52

7.7.1 Company Overview 52

7.7.2 Financials 52

7.7.3 Products 52

7.7.4 Strategies 52

7.7.5 Key Developments 52




TABLE 1 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 20

TABLE 2 MIDDLE EAST & AFRICA COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 21

TABLE 3 MIDDLE EAST & AFRICA COAGULATION FACTOR MARKET BY COUNTRIES, 2014 TO 2023 (USD MILLION) 22

TABLE 4 MIDDLE EAST & AFRICA RECOMBINANT COAGULATION FACTOR MARKET BY COUNTRIES,

2014 TO 2023 (USD MILLION) 23

TABLE 5 MIDDLE EAST & AFRICA PLASMA DERIVED COAGULATION FACTOR MARKET BY COUNTRIES,

2014 TO 2023 (USD MILLION) 24

TABLE 6 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 26

TABLE 7 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET FOR HAEMOPHILIA BY COUNTRY,

2014 TO 2023 (USD MILLION) 27

TABLE 8 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET FOR SURGERY BY COUNTRY,

2014 TO 2023 (USD MILLION) 28

TABLE 9 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET FOR OTHER BLEEDING DISORDERS BY COUNTRY,

2014 TO 2023 (USD MILLION) 29

TABLE 10 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET, BY COUNTRY, 2014 TO 2023 (USD MILLION) 31

TABLE 11 SAUDI ARABIA BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 32

TABLE 12 SAUDI ARABIA COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 32

TABLE 13 SAUDI ARABIA BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 33

TABLE 14 UNITED ARAB EMIRATES BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 34

TABLE 15 UNITED ARAB EMIRATES COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 34

TABLE 16 UNITED ARAB EMIRATES BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 35

TABLE 17 QATAR BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 36

TABLE 18 QATAR COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 36

TABLE 19 QATAR BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 37

TABLE 20 OMAN BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 38

TABLE 21 OMAN COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 38

TABLE 22 OMAN BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 39

TABLE 23 KUWAIT BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 40

TABLE 24 KUWAIT COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 40

TABLE 25 KUWAIT BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 41

TABLE 26 EGYPT BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 42

TABLE 27 EGYPT COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 42

TABLE 28 EGYPT BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 43

TABLE 29 REST OF MEA BLOOD COAGULANTS MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 44

TABLE 30 REST OF MEA COAGULATION FACTOR MARKET BY TYPE, 2014 TO 2023 (USD MILLION) 44

TABLE 31 REST OF MEA BLOOD COAGULANTS MARKET BY INDICATION, 2014 TO 2023 (USD MILLION) 45

FIGURE 1 RESEARCH PROCESS OF MRFR 10

FIGURE 2 MIDDLE EAST & AFRICA MARKET: FORECAST MODEL 12

FIGURE 3 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY TYPE, 2016 & 2023 (USD MILLION) 19

FIGURE 4 MIDDLE EAST & AFRICA COAGULATION FACTOR MARKET BY TYPE, 2016 & 2023 (USD MILLION) 20

FIGURE 5 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY INDICATION, 2016 & 2023 (USD MILLION) 25

FIGURE 6 MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET, BY COUNTRY, 2016 & 2023 (USD MILLION) 30